KENJI M. CUNNION, M.D.
Medical Practice at Childrens Ln, Norfolk, VA

2010005, Mar 4, 2010

May 25, 2007

12/304717

Neel K. Krishna - Norfolk VA, US
Kenji Cunnion - Norfolk VA, US

EASTERN VIRGINIA MEDICAL SCHOOL - Norfolk VA

A61K 39/12, C07K 14/005, A61K 38/16, A61K 39/395, A61P 31/12

4241411, 530350, 530300, 514 12, 4242041, 4241991

The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives.

2013005, Mar 7, 2013

Jul 17, 2012

13/551478

Neel K. KRISHNA - Norfolk VA, US
Kenji CUNNION - Norfolk VA, US

EASTERN VIRGINIA MEDICAL SCHOOL - Norfolk VA

A61K 39/12, A61P 19/04, A61P 25/00, A61P 21/04, A61P 7/06, A61P 17/02, A61P 31/12, A61P 11/00, A61P 9/10, A61P 37/06, A61P 25/28, A61P 29/00, A61P 13/12

4242041

The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives.

2006018, Aug 24, 2006

Feb 24, 2005

11/063721

Kenji Cunnion - Norfolk VA, US

A61K 39/085, C12N 1/21

424243100, 435252300

A method for enhancing the immune response of a patient to infection comprising administering to said patient an effective amount of agent that inhibits the cofactor that mediates (1) the removal of C3b by factor I from cells to which it has bonded by factor I and/or 2) the cleavage of C3b by factor I to forms inactive as opsonins for cells.

2013024, Sep 19, 2013

Jul 21, 2011

13/809371

Neel K. Krishna - Norfolk VA, US
Kenji M. Cunnion - Norfolk VA, US

C07K 14/08, A61K 45/06, A61K 38/16

514 11, 530324, 530326

The disclosure provides peptide compounds that regulate the complement system and methods of using these compounds. Specifically the disclosure provides an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The peptide compounds disclosed include peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and/or substitutions, deletions and/or substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The disclosure further provides pharmaceutical compositions comprising therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.